Department of Ophthalmology, Dongtan Sacred Heart Hospital, Hwaseong-si, Gyeonggi-do, Korea.
Department of Ophthalmology, Hallym University Sacred Heart Hospital, Anyang-si, South Korea.
Sci Rep. 2024 Oct 10;14(1):23676. doi: 10.1038/s41598-024-71895-1.
This study aimed to assess the efficacy of hyperbaric oxygen therapy (HBOT) in patients with central retinal artery occlusion (CRAO) by analyzing changes in visual acuity (VA) and enhanced depth imaging optical coherence tomography (EDI-OCT) parameters. A comparative retrospective study was conducted by reviewing the medical records of all HBO-treated RAO patients in our department and comparing them with matched RAO patients who did not receive HBO treatment. All patients treated with HBO received treatment within 7 days of the onset of visual symptoms. Baseline characteristics were compared, and VA and OCT parameters were evaluated at baseline and follow-up visits. A total of 50 eyes from 50 patients were included, with 29 eyes in the HBOT group and 21 eyes in the control group. The mean BCVA of the HBOT group at the initial visit was 2.03 logMAR, which improved to 1.55 logMAR at 6 months, with the change being statistically significant (P < 0.01), while the control group's BCVA remained almost unchanged, from 2.1 to 2.11 logMAR (P = 0.762). The central choroidal thickness increased significantly in the HBOT group over the subsequent period. The central fovea, and outer retinal layer thickness in the HBOT group were significantly greater than those in the control group at the 6-month follow-up after treatment. HBOT appears to be effective in improving VA and inducing favorable changes in OCT parameters in patients with CRAO. It helps to preserve retinal layer thickness, especially in the outer retinal layer.
本研究旨在通过分析视力(VA)和增强深度成像光相干断层扫描(EDI-OCT)参数的变化来评估高压氧治疗(HBOT)对视网膜中央动脉阻塞(CRAO)患者的疗效。通过回顾分析我科所有接受 HBO 治疗的 RAO 患者的病历,并与未接受 HBO 治疗的匹配 RAO 患者进行比较,进行了一项比较回顾性研究。所有接受 HBO 治疗的患者均在发病后 7 天内接受治疗。比较了基线特征,并在基线和随访时评估了 VA 和 OCT 参数。共纳入 50 例患者的 50 只眼,HBOT 组 29 只眼,对照组 21 只眼。HBOT 组初次就诊时的平均 BCVA 为 2.03 logMAR,6 个月时提高到 1.55 logMAR,差异有统计学意义(P<0.01),而对照组的 BCVA 几乎不变,从 2.1 到 2.11 logMAR(P=0.762)。HBOT 组在随后的时间内,脉络膜中央厚度明显增加。HBOT 组治疗后 6 个月时,中心凹、外层视网膜厚度均明显大于对照组。HBOT 似乎可有效提高 CRAO 患者的 VA 并诱导 OCT 参数的有利变化。有助于保持视网膜层厚度,特别是在外层视网膜。